Anne Aicher

Recorded in internal study records as H. D. Aicher, this researcher is principally associated with a series of clinical and experimental investigations into ayahuasca‑inspired combinations of N,N‑dimethyltryptamine (DMT) and harmine. Their work, as listed in the institutional database, includes factorial pharmacokinetic/pharmacodynamic dose‑escalation studies in healthy volunteers, randomised controlled trials assessing effects on mindfulness and compassion, and controlled investigations of potential therapeutic effects relevant to anxiety and depressive disorders. Aicher's projects span mechanistic pharmacology (interaction of DMT and harmine), behavioural and cognitive endpoints (creative thinking dynamics during artistic creation), and neurophysiological measures (changes in brain differentiation between self and other faces), indicating a translational focus from drug kinetics to psychological and neural outcomes.

Aicher appears to operate primarily in early‑phase human experimental medicine paradigms—studying safety, tolerability, dose interactions and acute psychological effects in volunteer populations—rather than late‑phase clinical efficacy trials. Their contributions are notable for integrating PK/PD methodology with psychometric, cognitive and neuroimaging endpoints to characterise how combined tryptamine/MAO‑inhibitor formulations modulate self‑processing, creativity, social‑affective variables and constructs relevant to mood and anxiety. External public records for the researcher under the initials H. D. Aicher were not found in the supplied search results; the profile is therefore synthesised from internal trial and manuscript records.